NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
Last week was full of exciting news. Genmab announced better-than-expected sales numbers for Darzalex at close to USD 2.7 billion, Expres2ion completed a GLP safety study, Evaxion completed dosing of the first patient in a study, Curasight got approval to start a new study with Curium, and Pila Pharma announced a new chairman and CEO. The best stock of the week rose almost 300%.
10 of the 21 Danish companies had a positive share price development the past week and 8 companies have had a positive share price performance year-to-date. Gubra is now the best-performing Danish healthcare stock year-to-date with a 126% return and Pila Pharma was the best Nordic healthcare investment last week.
Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.
DANISH COMPANY NEWS